This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, Adverse Events(AEs), and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA™ administration.
Recurrence of Clostridium Difficile Infection
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (primary and recurrent: severity, treatment), CDI-related symptoms, treatments, medical procedures, Adverse Events(AEs), and healthcare resource utilization (i.e., hospitalizations and re-admissions) will be collected through 6 months of follow-up from the date of REBYOTA™ administration.
REBYOTA™ Prospective Registry
-
Ferring Investigational Site, Chula Vista, California, United States, 91910
Ferring Investigational Site, Murrieta, California, United States, 92563
Ferring Investigational Site, Hamden, Connecticut, United States, 06518
Ferring Investigational Site, Gainesville, Florida, United States, 32610
Ferring Investigational Site, Orlando, Florida, United States, 32806
Ferring Investigational Site, Port Orange, Florida, United States, 32127
Ferring Investigational Site, Tampa, Florida, United States, 33614
Ferring Investigational Site, Zephyrhills, Florida, United States, 33542
Ferrin Investigational Site, Atlanta, Georgia, United States, 30322
Ferring Investigational Site, LaGrange, Georgia, United States, 30240
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Ferring Pharmaceuticals,
Global Clinical Compliance, STUDY_DIRECTOR, Ferring Pharmaceuticals
2025-08-01